Table 4.
Uni- and multivariable analyses for identifying predictors of pCR
| Variables | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |
| Gender (Female vs male) | 1.601 | 0.758-3.382 | 0.218 | - | - | - |
| Age (<65 vs ≥65 years) | 1.099 | 0.437-2.762 | 0.841 | - | - | - |
| Primary tumor | ||||||
| T category(T1-2 vs T3-4) | 2.448 | 1.043-5.748 | 0.040 | 3.131 | 1.213-8.082 | 0.018 |
| N category (N0 vs N1-2) |
1.497 | 0.702-3.189 | 0.296 | - | - | - |
| Location(Right vs left) | 2.799 | 1.273-6.066 | 0.010 | 2.808 | 1.198-6.580 | 0.017 |
| Liver metastases | ||||||
| Presentation time (Metachronous vs synchronous) | 0.936 | 0.462-2.314 | 0.994 | - | - | - |
| Tumor size (<3 vs ≥3 cm) |
29.504 | 3.986-218.39 | 0.001 | 20.542 | 2.738-154.139 | 0.003 |
| Tumor number (Single vs multiple) |
1.199 | 0.519-2.769 | 0.671 | - | - | - |
| RAS status (Wild-type vs mutated) | 1.618 | 0.725-3.610 | 0.240 | - | - | - |
| Oxaliplatin based chemotherapy (Yes vs No) |
1.971 | 0.829-4.690 | 0.125 | - | - | - |
| Irinotecan based chemotherapy (No vs Yes) |
2.749 | 1.103-6.85 | 0.030 | 2.231 | 0.856-5.814 | 0.100 |
| Bevacizumab (No vs Yes) |
1.148 | 0.513-2.566 | 0.737 | - | - | - |
| Cetuximab (No vs Yes) |
1.535 | 0.574-4.106 | 0.393 | - | - | - |
| Response to chemotherapy (Stable/Progression vs Complete/Partial) |
1.582 | 0.751-3.331 | 0.228 | - | - | - |
| Preoperative CEA (≤20 ng/mL vs >20 ng/mL) | 12.919 | 1.743-95.764 | 0.012 | 7.656 | 1.005-58.347 | 0.049 |
pCR, pathological complete response; CEA, carcinoembryonic antigen; Response to chemotherapy, tumor response to the last-line chemotherapy; OR, odds ratio; CI, Confidence Interval.